Compare AbbVie Inc (ABBV) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs General Motors Company — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while General Motors Company trades at $75.4 (market cap $68.55B). The key difference: AbbVie Inc is far larger — about 6.6× General Motors Company's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GM | |
|---|---|---|
Market Cap | $449.91B | $68.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $86.38 |
52-Week Low | $184.85 | $48.89 |
Enterprise Value | $513.38B | $171.89B |
Dividend Yield | 2.72% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
General Motors (GM) trades at $76.03, showing minimal daily movement with a 0.04% gain. The stock presents a mixed technical picture with bearish moving averages but oversold RSI conditions. Fundamentally, GM demonstrates strong cash flow generation ($26.9B operating cash flow in 2025) and consistent earnings beats, though profit margins remain thin at 1.38%. Recent news highlights strategic partnerships with Micron Technology and ongoing EV transition challenges.
GM offers value with attractive valuation multiples (P/S: 0.4x, P/B: 1.12x) and analyst consensus pointing to 31% upside potential. However, investors face risks from cyclical auto demand, margin pressure, and high debt levels. The company's scale and cash flow strength provide stability, but execution on EV strategy remains critical for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
